Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Vilas Zornoza, Amaia ^a   Agirre, Xabier ^a   Martín Palanco, Vanesa ^b   Martín Subero, José Ignacio ^c   José Eneriz, Edurne ^a   Garate, Leire ^a   Álvarez, Sara ^d   Miranda, Estíbaliz ^a   Rodríguez Otero, Paula ^a   Rifón, José ^a   Torres, Antonio ^b   Calasanz, María José ^e   Cigudosa, Juan Cruz ^d   Román Gómez, José ^b   Prósper, Felipe ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGED; APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CARCINOGENESIS; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; DNA MICROARRAY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROMOTER REGION; RETROSPECTIVE STUDY; ADULT; COHORT ANALYSIS; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE SILENCING; GENETICS; INFANT; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PRESCHOOL CHILD; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE FREQUENCY; GENE SILENCING; HUMANS; INFANT; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79952225602     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017012     Document Type: Article

References (58)

1. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30: 41-47.
2. Faderl S, Kantarjian HM, Talpaz M, Estrov Z, (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91: 3995-4019.
3. Armstrong SA, Look AT, (2005) Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 23: 6306-6315.
4. Pui CH, Relling MV, Downing JR, (2004) Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548.
5. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, et al. (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360: 470-480.
6. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, et al. (1993) Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82: 3163-3169.
7. Agirre X, Novo FJ, Calasanz MJ, Larrayoz MJ, Lahortiga I, et al. (2003) TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog 38: 201-208.
8. Gal-Yam EN, Saito Y, Egger G, Jones PA, (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59: 267-280.
9. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, et al. (2009) Epigenetics of acute lymphocytic leukemia. Semin Hematol 46: 24-32.
10. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, et al. (2007) Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109: 3462-3469.
11. Agirre X, Roman-Gomez J, Jimenez-Velasco A, Garate L, Montiel-Duarte C, et al. (2006) ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 25: 1862-1870.
12. Roman-Gomez J, Agirre X, Jimenez-Velasco A, Arqueros V, Vilas-Zornoza A, et al. (2009) Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 27: 1316-1322.
13. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, et al. (2002) DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8: 2217-2224.
14. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, et al. (2008) Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22: 1529-1538.
15. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
16. Calvanese V, Horrillo A, Hmadcha A, Suarez-Alvarez B, Fernandez AF, et al. (2008) Cancer genes hypermethylated in human embryonic stem cells. PLoS ONE 3: e3294.
17. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
18. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466.
19. San Jose-Eneriz E, Agirre X, Roman-Gomez J, Cordeu L, Garate L, et al. (2006) Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. Br J Haematol 134: 137-144.
20. Roman-Gomez J, Jimenez-Velasco A, Cordeu L, Vilas-Zornoza A, San Jose-Eneriz E, et al. (2007) WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer 43: 2736-2746.
21. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, et al. (2006) CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 12: 4845-4850.
22. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, et al. (2005) Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 23: 7043-7049.
23. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, et al. (2009) A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 4: e6986.
24. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, et al. (2009) Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114: 5490-5498.
25. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, et al. (2010) DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115: 1214-1225.
26. Davidsson J, Lilljebjorn H, Andersson A, Veerla S, Heldrup J, et al. (2009) The DNA methylome of pediatric acute lymphoblastic leukemia. Hum Mol Genet 18: 4054-4065.
27. Milani L, Lundmark A, Nordlund J, Kiialainen A, Flaegstad T, et al. (2009) Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Res 19: 1-11.
28. Schafer E, Irizarry R, Negi S, McIntyre E, Small D, et al. (2010) Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood.
29. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, et al. (2008) Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319: 336-339.
30. San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, Cordeu L, Martin V, et al. (2009) Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer 45: 1877-1889.
31. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, et al. (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213-7223.
32. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, et al. (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079-1082.
33. Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, et al. (2005) Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 14: 997-1007.
34. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, et al. (2005) Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11: 1380-1385.
35. Zhao J, Wu G, Bu F, Lu B, Liang A, et al. (2010) Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 51: 142-153.
36. Chim CS, Chan WW, Kwong YL, (2008) Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias. J Clin Pathol 61: 844-847.
37. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, et al. (2007) Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129: 879-890.
38. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, et al. (2005) Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 3: 325-334.
39. Wang HL, Bai H, Li Y, Sun J, Wang XQ, (2007) Rationales for expression and altered expression of apoptotic protease activating factor-1 gene in gastric cancer. World J Gastroenterol 13: 5060-5064.
40. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, et al. (2007) Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 97: 1457-1464.
41. Hagiwara K, Li Y, Kinoshita T, Kunishma S, Ohashi H, et al. (2010) Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma. Leuk Res 34: 50-54.
42. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M, (2005) Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 11: 4681-4688.
43. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, et al. (2008) Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 68: 4123-4132.
44. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, et al.(2009) Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One4: e8357.
45. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, et al. (2009) A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4: 255-264.
46. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP, (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873.
47. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, et al. (2007) Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26: 3473-3481.
48. Epstein J, Docena G, MacDonald TT, Sanderson IR, (2009) Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 103: 824-832.
49. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, et al. (1996) Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14: 18-24.
50. Ribera JM, Ortega JJ, Oriol A, Granada I, Hernandez-Rivas JM, et al. (2002) Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 87: 154-166.
51. Ribera JM, Ortega JJ, Oriol A, Fontanillas M, Hernandez-Rivas JM, et al. (1998) Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica 83: 222-230.
52. Ortega JJ, Ribera JM, Oriol A, Bastida P, Gonzalez ME, et al. (2001) Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Haematologica 86: 586-595.
53. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, et al. (2009) New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113: 2488-2497.
54. Aranda P, Agirre X, Ballestar E, Andreu EJ, Roman-Gomez J, et al. (2009) Epigenetic signatures associated with different levels of differentiation potential in human stem cells. PLoS One 4: e7809.
55. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, et al. (2009) Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69: 4443-4453.
56. Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, et al. (2002) 5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99: 2291-2296.
57. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, et al. (2002) Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94: 26-32.
58. Lo KW, Kwong J, Hui AB, Chan SY, To KF, et al. (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61: 3877-3881.